Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.57 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.57 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | IDH1 | O75874 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30577265 | 0.88 | SMN1; SMN2 (0.81) | NPC1RAB9ASMN1; SMN2CA2EPHX2 | |
| SCHEMBL7528507 | 0.82 | SMN1; SMN2 (0.67) | NPC1RAB9ASMN1; SMN2CA2EPHX2 | |
| SCHEMBL4118302 | 0.82 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2CA2EPHX2 | |
| SCHEMBL12584977 | 0.82 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2CA2EPHX2 | |
| SCHEMBL24495325 | 0.82 | SMN1; SMN2 (0.72) | NPC1RAB9ASMN1; SMN2CA2EPHX2 | |
| SCHEMBL11320359 | 0.81 | GNG2 (0.53) | NPC1RAB9ASMN1; SMN2CA2EPHX2 | |
| SCHEMBL3461319 | 0.81 | MEN1 (0.62) | NPC1RAB9ASMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL4111390 | 0.81 | SMN1; SMN2 (0.75) | NPC1RAB9ASMN1; SMN2CA2EPHX2 | |
| SCHEMBL11755742 | 0.80 | SMN1; SMN2 (0.69) | NPC1RAB9ASMN1; SMN2CA2EPHX2 | |
| SCHEMBL4089269 | 0.80 | NPC1 (0.58) | NPC1RAB9ACA2EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026357-B2 | Diphenylurea compounds | LES LABORATOIRES SERVIER (FR) | 2006-04-11 | — | — | US | disclosed |
| EP-1170288-B9 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | SERVIER LAB (FR) | 2005-01-26 | — | — | EP | disclosed |
| US-20040224993-A1 | Diphenylurea compounds | LAVIELLE GILBERT (FR) | 2004-11-11 | — | — | US | disclosed |
| US-6784183-B2 | ANTISEROTONINE AGENTS | LES LABORATOIRES SERVIER (FR) | 2004-08-31 | — | — | US | disclosed |
| EP-1170288-B1 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | SERVIER LAB (FR) | 2004-08-11 | — | — | EP | disclosed |
| US-20020025965-A1 | Antiserotonine agents | ADIR ET COMPAGNIE (FR) | 2002-02-28 | — | — | US | disclosed |
| EP-1170288-A2 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025965-A1 | Antiserotonine agents | HTR2C, HTR3C, HTR3A | NPC1 1974/4885RAB9A 4643/4885SMN1; SMN2 3439/4885 |
| US-20040224993-A1 | Diphenylurea compounds | HTR2C, HTR2A, HTR1A | NPC1 1584/4885RAB9A 3382/4885SMN1; SMN2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.